Dianthus Therapeutics Inc.

DNTH.US
Healthcare · Biotechnology
101.61
-2.88 (-2.76%)
USD · NASDAQ

Company Information

Company Name
Dianthus Therapeutics Inc.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US2528281080
CIK: 0001690585
CUSIP: 252828108
Currency: USD
Full Time Employees: 92
Phone: 929 999 4055
Fiscal Year End: December
IPO Date: Sep 12, 2023
Description:

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Address:

7 Times Square, New York, NY, United States, 10036

People

Directors & Officers

Name Title Year Born
Mr. Marino Garcia M.B.A. President, CEO & Director 1966
Mr. Ryan Savitz Executive VP, CFO, Chief Business Officer & Treasurer 1989
Dr. Simrat Randhawa M.B.A., M.D. Executive VP and Head of R&D 1970
Mr. Edward G. Carr Senior VP & Chief Accounting Officer 1969
Mr. Judson Taylor Senior VP & Head of Technical Operations NA
Ms. Jennifer Davis Ruff VP and Head of Investor Relations & Corporate Affairs NA
Mr. Adam M. Veness Esq. Senior VP, General Counsel & Secretary 1986
Ms. Kristina Maximenko Chief People Officer NA
Ms. Rashieda Gluck Head of Clinical Development Operations NA
Mr. Scott Nogi M.B.A. Head of Business Operations NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 09, 2026 Ryan Savitz N/A Sale 8.22K $89.84 $738.84K
Mar 31, 2026 Ryan Savitz N/A Sale 114.37K $83.00 $9.49M
Mar 12, 2026 Edward Carr N/A Sale 43.68K $81.49 $3.56M
Mar 12, 2026 Marino Garcia N/A Sale 122.92K $81.49 $10.02M
Mar 12, 2026 Simrat Randhawa N/A Sale 33.83K $81.48 $2.76M
Dec 04, 2025 Ryan Savitz N/A Sale 20.00K $45.18 $903.60K
Nov 14, 2025 Simrat Randhawa N/A Sale 109.03K $38.14 $4.16M
Nov 13, 2025 Simrat Randhawa N/A Sale 87.51K $36.81 $3.22M
Sep 09, 2025 Ryan Savitz N/A Sale 20.00K $35.00 $700.00K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
FMR Inc 7.77M Mar 31, 2026 14.21% $0.03 20.78%
Avidity Partners Management LP 4.21M Mar 31, 2026 7.70% $38.62 100.00%
BlackRock Inc 3.18M Mar 31, 2026 5.81% $0.00 65.81%
RA Capital Management, LLC 2.61M Mar 31, 2026 4.78% $2.32 62.05%
Wellington Management Company LLP 2.60M Mar 31, 2026 4.75% $0.04 3.70%
Fairmount Funds Management LLC 2.54M Mar 31, 2026 4.64% $15.38 18.72%
Vanguard Group Inc 2.05M Dec 31, 2025 3.75% $0.00 24.74%
Vanguard Capital Management, LLC 2.03M Mar 31, 2026 3.72% $0.00 0.00%
Octagon Capital Advisors LP 1.95M Mar 31, 2026 3.56% $18.08 -19.45%
TCG Crossover Management, LLC 1.68M Mar 31, 2026 3.07% $4.03 0.00%
Citadel Advisors Llc 1.61M Mar 31, 2026 2.95% $0.02 50.66%
State Street Corp 1.40M Mar 31, 2026 2.56% $0.00 -7.21%
T. Rowe Price Investment Management,Inc. 1.29M Mar 31, 2026 2.36% $0.07 0.00%
VR Adviser, LLC 1.18M Mar 31, 2026 2.16% $3.70 18.00%
Fred Alger Management, LLC 1.16M Mar 31, 2026 2.13% $0.43 3,372.57%
T. Rowe Price Associates, Inc. 1.15M Mar 31, 2026 2.10% $0.01 86.18%
Polar Capital Holdings PLC 1.08M Mar 31, 2026 1.97% $0.32 7.09%
Deerfield Management Co 1.02M Mar 31, 2026 1.87% $1.01 0.00%
Franklin Resources Inc 968.18K Mar 31, 2026 1.77% $0.02 109.19%
Cormorant Asset Management, LLC 950.00K Mar 31, 2026 1.74% $4.00 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Growth Compy Commingled Pl S 2.20M 4.03% ▲ 4.29% May 31, 2026
2 Vanguard Total Stock Mkt Idx Inv 1.65M 3.02% ▲ 4.95% Jun 30, 2026
3 Fidelity Growth Company Fund 1.59M 2.92% ▲ 5.13% May 31, 2026
4 Vanguard Health Care Inv 1.46M 2.67% ▼ 7.25% Mar 31, 2026
5 State Street® SPDR® S&P® Biotech ETF 1.30M 2.37% ▼ 2.17% Jun 30, 2026
6 iShares Russell 2000 ETF 1.22M 2.24% ▲ 0.60% Jun 30, 2026
7 T. Rowe Price US Small-Cap Core Equity 1.17M 2.15% ▲ 135.21% Jun 30, 2026
8 T. Rowe Price Small-Cap Stock 1.17M 2.15% ▲ 109.59% Jun 30, 2026
9 Polar Capital Biotech S Inc 964.85K 1.77% ▼ 5.19% May 31, 2026
10 Fidelity Advisor Biotechnology I 730.06K 1.34% ▲ 0.00% May 31, 2026

Financial Highlights

Market Cap: $5.71B
EBITDA: $-191.17M
Book Value: $22.01
Earnings/Share: $-4.23
Profit Margin: 0.00%
Operating Margin: -10,050.32%
ROA (TTM): -14.99%
ROE (TTM): -22.70%
Revenue (TTM): $1.34M
Revenue/Share (TTM): $0.03
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -60.20%

Valuation Metrics

Enterprise Value: $4.57B
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 54.67M
Shares Float: 54.60M
% Insiders: 12.70%
% Institutions: 12,151.90%
Short % Float: 19.42%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$2.04M
Gross Profit
subtotal
$2.04M
SG&A
adjust
$-34.33M
R&D
adjust
$-145.64M
Operating Income
subtotal
$-177.93M
Other / Non-Operating Items
adjust
$15.60M
Net Income
subtotal
$-162.34M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about DNTH.US!